

International Niemann-Pick Disease Registry Annual Forum

Thursday 6th October 2022

Venue: The Woodlands Event Centre, Wyboston Lakes, Great North Road, Wyboston, Bedfordshire, MK44 3ALUK

13.00 - 13.45	Lunch: The Olive Restaurant
13.45 – 17.30	INPDR Forum: Ash 1 & 2
13.45	Welcome and Introduction Jim Green, INPDR Board Chair
14.00	Setting the Scene Conan Donnelly, CEO, INPDR
14.15	INPDR Progress Report Shaun Bolton, Operations Consultant, INPDR
14.30	Growing the INPDR Jackie Imrie, Clinical Research Manager, INPDR
14.45	Capturing and making sense of patient reported data Conan Donnelly, CEO, INPDR
15.00	Linking and Curating NPD Data David Storey, DPO, INPDR
15.15	Making use of data - commercial studies, challenges and opportunities Shaun Bolton, Operations Consultant, INPDR
15.30	Refreshment Break: Paddy and Scott's Coffee House
15.45 - 16.45	Breakout Sessions
16.45	Feedback and listening session
17.00	Discussion and round up
17.30	Networking Reception: Olive 2
19.00	Dinner: Olive 2



Niemann-Pick UK 11th Interactive Workshop on Niemann-Pick Diseases

Friday 7th October 2022

Venue: The Woodlands Event Centre, Wyboston Lakes, Great North Road, Wyboston, Bedfordshire, MK44 3ALUK

09.00-09.30	Registration and Refreshments
09.30-09.35	Welcome and Introduction
	Professor Frances Platt
	Department of Pharmacology, University of Oxford, UK
9.35-10.50	Research Updates
09.35-9.45	Dysregulated Inflammation in NPC Frances Platt, PhD, FMedSci, FRS Head of Department of Pharmacology, University of Oxford
09.45-09.55	NPC1-PMCA2 complex in Niemann-Pick disease type C Maria E. Fernandez-Suarez, PhD Postdoctoral Researcher Department of Pharmacology, University of Oxford
09.55 -10.10	NPC1 and lysosome interactionsDr Andrea MartelloResearch Associate, Institute of Ophthalmology, Faculty of Brain Sciences,University College London
10.10 -10.20	Role of NPC1 protein in the persistence of intracellular pathogens Yuzhe Weng DPhil Student Department of Pharmacology, University of Oxford
10.20-10.35	In vitro attempts to treat the mitochondrial defect in NPCD Dr Simon Wheeler Lecturer in Pharmaceutical Chemistry, De Montfort University, Leicester
10.35-10.50	Discussion

11.15-12.30	Interactive Workshop 1: New Developments in Niemann-Pick diseases
11.15-11.35	Developing an optimized gene therapy strategy for Niemann-Pick Disease Type C1 Hemanth Ramesh Nelvagal MBBS, PhD Postdoctoral Research Associate, Rahim Group, University College London
11.35-12.00	Novel Therapeutic Strategies for Niemann Pick Type C Disease Kevin T. Vaughan Associate Professor of Cell Biology, University of Notre Dame, Indiana, USA
12.00-12.20	Niemann–Pick type C disease as proof-of-concept for intelligent biomarker panel selection in neurometabolic disorders Apostolos Papandreou Molecular Neurosciences, Developmental Neurosciences Programme, Great Ormond Street Institute of Child Health, University College London
12.20-12.30	Discussion

12.30-13.30 Lunch

13.30-14.20Interactive Workshop 2:
Drug Repurposing in Rare Diseases13.30-13.55Drug repurposing in rare diseases; the benefits and opportunities
Rick Thompson
CEO, Rare Beacon13.55-14.10Drug repurposing: a company perspective
Taylor Fields
Chief Product Development Officer, IntraBio Ltd.14.10-14.20Discussion

14.20-15.20	Interactive Workshop 3: Newborn and Future Screening
14.20-14.30	Introduction William Owen
	Trustee and Research Coordinator, NPUK
14.30-14.40	A Rare Life Lived Better; Newborn Screening Bob Stevens Group CEO, MPS Society & Rare Disease Research Partners Vice Chair, LSD Collaborative
14.40-15.20	 Panel Session: The benefits, challenges, and practicalities of newborn and future screening for Niemann-Pick and other rare genetic conditions. Dr Robin Lachmann, PhD, FRCP, Consultant in Metabolic Medicine, National Hospital for Neurology, London Prof. Paul Gissen, Consultant in Paediatric Metabolic Diseases, Great Ormond Street; Wellcome Trust Sr. Research Fellow in Clinical Sciences, UCL Karen Harrison, Support Services Manager, AlexTLC

15.20-15.35 Refreshment Break

15.35-16.30 Interactive Workshop 4: Predicting the Clinical Path and Severity of NPC 15.35-15.50 Challenges and Opportunities with the NPC Clinical Severity Scale (NPCCSS) Professor Marc C. Patterson, MD Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA 15.50-16.05 Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm 16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR Clinical disease characteristics of patients with NPC: findings from the INPDR		
15.35-15.50 Challenges and Opportunities with the NPC Clinical Severity Scale (NPCCSS) Professor Marc C. Patterson, MD Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA 15.50-16.05 Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine i Dali, MD Chief Medical Officer, KemPharm 16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR	15.35-16.30	Interactive Workshop 4:
Professor Marc C. Patterson, MD Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA15.50-16.05Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDRNiemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Predicting the Clinical Path and Severity of NPC
Professor Marc C. Patterson, MD Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA15.50-16.05Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDRNiemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		
Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA15.50-16.05Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDRNiemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR	15.35-15.50	Challenges and Opportunities with the NPC Clinical Severity Scale (NPCCSS)
Mayo Clinic Children's Center, Rochester, MN, USA15.50-16.05Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Professor Marc C. Patterson, MD
15.50-16.05 Natural History and Progression of NPC; Progression rates in NPC vary between individual patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm 16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Professor of Neurology, Pediatrics and Medical Genetics
patients due to the heterogeneity of the disease; What factors appear to influence annual progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm 16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Mayo Clinic Children's Center, Rochester, MN, USA
progression rates? Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Taking the next steps – supporting research Conan Donnelly, Chief Executive Officer, INPDRNiemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR	15.50-16.05	Natural History and Progression of NPC; Progression rates in NPC vary between individual
Christine í Dali, MD Chief Medical Officer, KemPharm16.05–16.30International Niemann-Pick Disease Registry (INPDR): Supporting Research Taking the next steps – supporting research Conan Donnelly, Chief Executive Officer, INPDRNiemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		patients due to the heterogeneity of the disease; What factors appear to influence annual
Chief Medical Officer, KemPharm 16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Taking the next steps – supporting research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		progression rates?
16.05–16.30 International Niemann-Pick Disease Registry (INPDR): Supporting Research Taking the next steps – supporting research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Christine í Dali, MD
Taking the next steps – supporting research Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Chief Medical Officer, KemPharm
Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR	16.05-16.30	International Niemann-Pick Disease Registry (INPDR): Supporting Research
Conan Donnelly, Chief Executive Officer, INPDR Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		Taking the next steps – supporting research
Niemann-Pick Type C – The patient reported experience, an NPUK led survey Solomon Mbua, CRA Consultant, INPDR		
Solomon Mbua, CRA Consultant, INPDR		
Clinical disease characteristics of patients with NPC: findings from the INPDR		Solomon Mbua, CRA Consultant, INPDR
		Clinical disease characteristics of patients with NPC: findings from the INPDR
Shaun Bolton, BSc, MSc, Operations Consultant, INPDR		Shaun Bolton, BSc, MSc, Operations Consultant, INPDR
Quality of life in patients with Niemann-Pick disease and their carers		Quality of life in patients with Niemann-Pick disease and their carers
Jackson Pountney, Psychology PhD student, Aston University		Jackson Pountney, Psychology PhD student, Aston University

16.30 - 17.35	Interactive Workshop 5: Clinical Updates
16.30-16.40	The impacts of olipudase alfa on paediatric patients with ASMD and their families Justin L. Hopkin, M.D. University of Rochester Medical Centre
16.40-16.50	Clinical Development of Olipudase Alfa for ASMD NPB Dr Robin Lachmann PhD, FRCP National Hospital for Neurology and Neurosurgery, London
16.50-17.05	Fifteen years from discovery to bedside: HPβCD, where to now?" Caroline Hastings MD UCSF Benioff, USA
17.05-17.15	Oral, dental and craniofacial features in chronic acid sphingomyelinase deficiency Dra Cláubia Viegas Bender Dentist and Researcher, Universidade Federal do Rio Grande do Sul, Brazil
17.15-17.25	Development of Clinical Guidelines for ASMD Shaun Bolton, BSc, MSc Operations Consultant, INPDR
17.25-17.35	Discussion

17.35-17.45 Community Voices: Living with Niemann-Pick Diseases

17.45Workshop CLOSE18.00-19.00Networking Reception:
Rosewood Foyer and Conservatory

NPUK is a charitable organisation dedicated to making a positive difference to the lives of those affected by Niemann-Pick diseases. We raise much needed awareness, provide practical and emotional support, advice and information and facilitate research into potential therapies.

Niemann-Pick UK

Registered Charity Number: 1144406 | Registered as a Charity in Scotland No. SCO45407 Suite 2, Vermont House, Washington, Tyne and Wear, NE37 2SQ, UK Telephone: 00 44 (0)191 415 0693 Email: <u>info@npuk.org</u> Website_npuk.org

With grateful thanks to our Sponsors and Grant Funders:

We rely entirely on voluntary donations, charitable grants and fundraising to support our work with those affected by Niemann-Pick diseases, their families and the health professionals caring for them. We are hugely grateful to all who have provided support for this event:



Cyclo Therapeutics, Inc. provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers.



KemPharm provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers



Azaforos provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers



Niemann-Pick UK aims to ensure the patients and families we support are equipped and empowered with up-to-date and accurate information about Niemann-Pick disease, including the latest research and clinical trial information.

Our annual events provide an ideal opportunity to be able to do this, as many of our families attend, alongside our healthcare professional colleagues and pharmaceutical company representatives.

As research advances and an increasing number of clinical trials are initiated, it is even more critical that the information we provide to our families at our conference and through all our other communication is up-to-date, accurate and balanced.

Therefore, as we facilitate this exchange of scientific information, we would like to remind attending pharmaceutical companies that all communications and interactions at our conference must abide by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice available here: <u>https://www.pmcpa.org.uk/</u>

This includes ensuring all information provided is balanced, fair, up-to-date, accurate, not misleading in any way and capable of substantiation.

We aim to be as transparent and as fair as possible with our families, healthcare professional colleagues and pharmaceutical company representatives and we ask for the same conduct in return.

Making a difference to the lives of those affected by Niemann-Pick

Registered Charity: England and Wales (1144406) / Scotland (SCO45407) Registered as a company limited by guarantee in England and Wales (07775835)



Annual Family Conference Programme of Events

7th - 9th October 2022

Woodlands Event Centre Wyboston Lakes, Great North Road, Wyboston, Bedfordshire, MK44 3AL, UK





Dear Families, Friends, and Supporters,

On behalf of the NPUK Board of Trustees, I have pleasure in welcoming you to our flagship events - the Interactive Workshop on Niemann-Pick Diseases and our Family Conference. We are pleased to be back at Wyboston Lakes; and to be able to bring our community together with once again.

As in previous years, the programme is full of interesting and valuable talks, presentations, and workshops, which will cover many thought-provoking areas of research and advances in treatments. As we reach new milestones in terms of developments and stages in research, I think it is always important to take a look at just how far we have came - such advances that we speak of today would have been simply unthinkable when NPUK began in 1991.

Although we still have a long way to go, and at times the road can appear unsure, I find it encouraging to look upon the progress we have achieved together as a community, and to remind myself that it is as a community that we will continue to make progress.

I for one am very much looking forward to being able to reunite with many familiar faces in the community, as well as offer a warm welcome to those who have recently joined NPUK. If you feel a little apprehensive as this is your first time at Conference, just remember that everyone has been in your position at one stage, we are a very friendly bunch, and I am sure you will find it an inspiring experience - it's no coincidence that our community members return year on year!

The NPUK staff and trustees, along with the friendly and efficient team at the Woodlands Event Centre, are here to ensure you have an enjoyable stay at our event. Please feel free to speak to a member of either team should you have any questions about the venue or your accommodation.

I hope you will find your experience at our Conference informative and rewarding. If you need any help at all, please ask – NPUK representatives will be happy to assist you.

With best wishes,

Will

Dr. William Evans Chair, NPUK

Delegate Information – The Woodlands Event Centre

On Arrival

The Woodlands Event Centre has free parking on-site including designated spaces for disabled guests (located close to the main entrance).

The Woodlands Event Centre Reception

Reception is open from 7.00am until 10.30pm; a night porter is on duty outside these hours.

You will be able to check into your accommodation any time from 3.00pm on your arrival day. Early check-in rooms can be arranged if required. The Hotel respectfully request that you check out of your accommodation by 11.00 on the day of departure, unless otherwise arranged. To pre-book a late checkout room, please speak to a member of the NPUK team or book direct with the hotel reception. A secure luggage store is available at reception.

Niemann-Pick UK Registration Desk

The NPUK registration desk will be available in the Cedar lounge from 08.30 on Friday 7th October, until 12.30on Sunday 9th October. NPUK team members will be available to assist you with any queries regarding the hotel or the Conference programme/activities. You can also approach team members or NPUK Trustees for help or information at any time.

Accommodation

All bedrooms are en-suite and include tea and coffee making facilities, hairdryer and toiletries, ironing facilities, TV, and Wi-Fi internet access. There is a strict "**No Smoking or Vaping**" policy in bedrooms and throughout the Woodlands Event Centre.

Meals

All meals will be served in the Olive Restaurant:

Breakfast	Lunch	Dinner
Weekdays: 7.00-9.00	Please refer to the	Thursday 6 th October, 19.00-21.00
Weekends: 7.00-10.00	Conference programme for	Friday 7 th October 18.30- 21.00
	timings.	Saturday 8 th October: Gala Dinner 19.00 prompt

Refreshments will be available throughout the event from Paddy and Scott's Coffee House, located close to Reception.

Entertainment and Leisure Facilities

The hotel has a Health and Fitness Club situated on site, with a heated swimming pool, sauna, and steam room plus a fully equipped gym. Access is free of charge for NPUK Conference delegates. Please be advised that due to health and safety regulations children under the age of 16 years need to be accompanied by an adult, one for every 2 children, regardless of their swimming abilities.

The site also boasts a Spa (www.yspa.co.uk), a superb 18-hole golf course, an all-weather driving range and a water sports centre. Charges for these facilities are payable locally. For further information, please contact hotel reception or visit <u>http://www.wybostonlakes.co.uk/golf</u>

Bar facilities will be available in the main lounge from 15.00 until 23.00. **Please note that the Woodlands Event Centre does not accept cash - card payments only.** Following our Gala Dinner on Saturday evening, delegates will be entertained with live music from party band, *Makapaka*. Throughout the weekend, you can join our raffle, browse our craft stall, and try your hand at our tombola, all staffed by members of our wonderful volunteer team.

Medical Assistance

Bedford Hospital (MK42 9DJ) and Hinchingbrook Hospital (PE29 6NT) are within 10 miles of the locality and Addenbrooke's Hospital in Cambridge (CB2 0QQ) have A&E facilities if required.

Session Guide:

For Joint Sessions follow:	
For NP-C Sessions follow:	
For ASMD Sessions follow:	
Children and Young Adults' Activity Programme:	
Reflections	

This is YOUR Conference!

- We aim to create an informal atmosphere in which everyone feels comfortable
- ✓ Please always wear your badge
- ✓ Drop in and drop out feel free to come and go during sessions
- You will be able to connect with family and professional delegates during coffee, lunch, and social time
- Refreshment stations will be available throughout the weekend, please help yourself at any time
- If you would like to, you can add your personal thoughts and messages to our Wishing Tree
- You will find our registration desk in the Cedar Lounge. For help or advice, please approach a member of the NPUK Team at any time
- Be "Social"! Help NPUK to raise awareness by sharing your photos and experiences of Conference across social media, using any of the following hashtags #NPUKAFC22 #NPUKIW22 #TeamNPUK #NPUKFamily #NiemannPickUK #NPUK

Friday 7th October 2022

08.30	Registration
	The Interactive Workshop on Niemann-Pick Diseases

09.00-17.45	The Interactive Workshop on Niemann-Pick Diseases Rosewood Suite
15.00	Check-in and Registration NPUK Family Conference
16.00-18.00	Patient and Carer Focus Group (Closed session – invitation only) Beech 1
18.30 - 21.00	Dinner The Olive Restaurant
19.00 - 20.30	Children and Young Persons' Activity Programme: Movie Time! Beech 2 All children and young people are welcome to this supervised session.
19.00 - 20.30	Getting to Know You Rosewood 2 & 3 Join us at one of the following informal sessions to say hello, get to know other family delegates and meet NPUK Staff members and Trustees
20.30	Children and Young Persons' Activity Programme: Volunteer Briefing Beech 2

Saturday 8th October 2022

8.30 - 9.00	Conference Registration Cedar Lounge
8.30 - 9.00	Children and Young Adults' Activity Programme Registration Beech 2

09.00- 10.40	Joint Sessions Rosewood Suite
09.00	Welcome and Overview Dr William Evans Chair, NPUK
09.10 - 10.00	Where are we now? Research update on NPC: where are we now? Frances Platt, PhD, FMedSci, FRS Head of Department of Pharmacology, University of Oxford
	The clinical trial landscape for Niemann-Pick type C disease Professor Marc C. Patterson, MD FRACP Professor of Neurology, Pediatrics and Medical Genetics Mayo Clinic Children's Center, Rochester, MN, USA
	ASMD: an overview of research and clinical options Dr Robin Lachmann, PhD, FRCP Consultant in Metabolic Medicine, National Hospital for Neurology, London Questions and discussion
10.00 - 10.40 Cedar Lounge	Where do we want to be? Research and Therapy Development: Community voices, hopes and expectations
10.40 - 11.00	Refreshment Break Paddy and Scott's Coffee House

11.00- 11.30	Joint Sessions Rosewood Suite How do we get there?
11.00 - 11.30	Drug repurposing in rare diseases; the benefits and opportunities Rick Thompson CEO, Rare Beacon

11.30 - 12.45	Parallel Sessions	
NPC Sessions: Rosewood Suite		ASMD Sessions: Ash 1 & 2
NPC Research Up	odates	ASMD Research and Clinical Updates
 11.35 -12.00 Altered Inflammation in NPC Frances Platt, PhD, FMedSci, FRS Head of Department of Pharmacology, University of Oxford 12.00-12.20 Role of NPC1 Protein in the persistence of intracellular pathogens Yuzhe Weng DPhil Student Department of Pharmacology, University of Oxford 		 11.35 -11.55 Clinical Development of Olipudase Alfa for ASMD NPB Dr Robin Lachmann PhD, FRCP National Hospital for Neurology and Neurosurgery, London 11.50 -12.20 The impacts of olipudase alfa on paediatric patients with ASMD and their families Justin L. Hopkin, M.D. University of Rochester Medical Centre 12.20 - 12.45
Notre Dame Kevin T. Vaughan	efforts at the University of or of Cell Biology, University of na, USA	Development of Clinical Guidelines for ASMD Shaun Bolton, BSc, MSc Operations Consultant, INPDR and Justin L. Hopkin, M.D., University of Rochester Medical Centre

12.45-13.45

13.45- 14.30 Rosewood Suite	Joint Sessions		
13.45-14.30	Newborn screening: opportunities and challenges: Introduction William Owen Trustee and Research Coordinator, NPUK A Rare Life Lived Better; Newborn Screening		
	Bob Stevens Group CEO, MPS Society & Rare Disease Research Partners Vice Chair, LSD Collaborative		
	Panel Discussion: The benefits, challenges, and practicalities of newborn and future screening for Niemann-Pick and other rare genetic conditions.		
	 Dr Robin Lachmann, PhD, FRCP, Consultant in Metabolic Medicine, National Hospital for Neurology, London 		
	 Prof. Paul Gissen, Consultant in Paediatric Metabolic Diseases, Great Ormond Street; Wellcome Trust Sr. Research Fellow in Clinical Sciences, UCL 		
	 Karen Harrison, Support Services Manager, AlexTLC 		
14.30 – 15.20	Parallel Sessions		
	PC Sessions: sewood Suite	ASMD Sessions: Ash 1 & 2	
		14.30 Sanofi Rare Disease Programme Ben Whitehouse, Head of Rare Diseases, UK Sanofi	
Maryland, USA Pro Prof. Paul Gissen, Metabolic Disease		14.55 An approved therapy for ASMD; what can we expect? Discussion facilitated by ASMD community members James Brooks and James Dyson, with guest speaker Bob Stevens, Rare Disease Dad.	

15.20 - 15.40	Refreshment Break	
	Paddy and Scott's Coffee House	

15.40- 17.00 Rosewood Suite	Joint Sessions
15.40 - 16.30	Panel Session: Clinical Development, Past, Present and Future This is your opportunity to ask our experts any burning questions you have about clinical trials and development.
16.30 - 17.00	Invisible Interviews: Niemann-Pick diseases John Lee Taggart NPUK Communications Manager and Lingxi Zhang, Animator and Creative Director
17.00	Day 1 Close
19.00	Gala Dinner
19.00	Gala Dinner Rosewood Suite Please check the seating plan for your table number.
19.00 20.00	Rosewood Suite

Sunday 9th October 2022

09.00	Children and Young Persons' Activity Programme
	Beech 2 and Salix Suite

09.30	Welcome to Day 2 Rosewood Suite	
09.35 – 10.45	Breakout Session: Emotional Resilience against anxiety, stress, and depression Poplar Steven Neal NPUK Counselling and Wellbeing Officer	
09.35 -10.45	Joint Sessions Rosewood Suite	
09.35	 INPDR: International Niemann-Pick Disease Registry Patient Reported Data Jackie Imrie, Clinical Research Manager Niemann-Pick Type C – The patient reported experience, an NPUK led survey Conan Donnelly, Chief Executive Officer, INPDR Quality of life in patients with Niemann-Pick disease and their carers Jackson Pountney, Psychology PhD student, Aston University Home Based Monitoring Claire Fyvie, NPUK Trustee (Co-opted) Solomon Mbua, CRA Consultant, INPDR Jackie Imrie, Clinical Research Manager 	
10.30	Web-based animations to inform and connect patients and support organisations Maria E. Fernandez-Suarez, PhD Postdoctoral Researcher Department of Pharmacology, University of Oxford	

10.45 - 11.15	Refreshment Break and Check-out Paddy and Scott's Coffee House

11.15-12.30	Joint Sessions Rosewood Suite	
11.15 -11.35	Physical Therapy in Niemann-Picl Alvaro Berzal Gomez Paediatric Physiotherapist	k Diseases
11.35 -12.00	NPUK: Meet our Care & Support Team Laura Bell, Clinical Nurse Specialist Louise Metcalfe, Families Officer Steve Neal, Counselling and Wellbeing Officer	
12.00 -12.20	The Impact of Fundraising Jenny Geere NPUK Fundraising Officer	
12.20-12.30	Closing Remarks	
		en Carter Joella Melville stee, NPUK Trustee, NPUK
12.30-13.30	Lunch The Olive Restaurant	
	Please return your badges and a Reception Desk. Thank you!	completed evaluation forms to the NPUK
	lov	Huge thanks to everyone who has attended or contributed to this event, we simply couldn't do it without you!

NPUK is a charitable organisation dedicated to making a positive difference to the lives of those affected by Niemann-Pick diseases. We raise much needed awareness, provide practical and emotional support, advice, and information, and facilitate research into potential therapies.

We rely entirely on voluntary donations, charitable grants, and fundraising to support our work with those affected by Niemann-Pick diseases, their families and the health professionals caring for them.

We are hugely grateful to all who have provided support for this event:







Cyclo Therapeutics, Inc. provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers.



KemPharm provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers



Azaforos provided financial support for this event via an unrestricted educational grant without control or influence of the content of the programme or the selection of speakers

npuk

Making a difference to the lives of those affected by Niemann-Pick

Registered Charity: England and Wales (1144406) / Scotland (SCO45407) Registered as a company limited by guarantee in England and Wales (07775835)